Novartis recognised for efforts in cancer
pharmafile | August 8, 2013 | News story | Medical Communications, Sales and Marketing |Â Â Bush, CEO, Cancer, NovartisÂ
Novartis is the first company to earn a global CEO Cancer Gold Standard accreditation by the non-profit organisation CEO Roundtable on Cancer.
The body was founded in 2001 when former President George Bush challenged a group of executives to “do something bold and venturesome about cancer within your own corporate families.”
The CEOs responded by creating and encouraging the widespread adoption of the CEO Cancer Gold Standard, which calls for organisations to evaluate their health benefits and workplace culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace.
The Roundtable on Cancer has now recognised Novartis’ efforts to support associates in the prevention, diagnosis and treatment of cancer.
“At Novartis, we believe that everyone should have access to early screening programmes and innovative therapies,” said Joseph Jimenez, chief executive of Novartis. “Our efforts for our associates, which are recognised by this designation, are an extension of our goal to redefine cancer for all patients.”
Novartis first achieved CEO Cancer Gold Standard designation in the US, and quickly extended these resources around the world. The impact it says has been significant.
Through the Novartis cancer-screening programme alone, the company has already documented cases of early cancer detection among its associates and has been able to offer the kind of support and treatment that helps to change lives.
Novartis added that it continues to expand the programme to leverage the company’s internal expertise and expand its cancer network and resources to support employees and their families with the best medical, emotional and physical support possible.
Brett Wells
Related Content
Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …
Novartis candidate for Sjögren’s disease presents positive results
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …
Central nervous system cancer metastases – the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds
